59
Participants
Start Date
December 20, 2016
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Itacitinib
In Phase 1, itacitinib at a protocol-defined starting dose, with subsequent dose escalation based on protocol-specific criteria. In Phase 2, itacitinib at the recommended dose from Phase 1.
Osimertinib
Osimertinib 80 mg once daily (QD)
National Taiwan University Hospital, 7 Zhongshan South Road, Taipei
NYU Langone Medical Center, 160 East 34th Street, Floor 8, New York
Taipei Veterans General Hospital, No.201 Sec. 2 Shipai Rd l, Taipei
Stony Brook University Medical Center, 3 Edmund D. Pellegrino Road, Stony Brook
St. Luke's University Health Network, 701 Ostrum Street, Suite 403, Fountain Hill
Thomas Jefferson University, 111 S. 11th Street, Philadelphia
Georgetown University Hospital, 3800 Reservoir Rd, NW, Washington D.C.
US Oncology-Virginia Cancer Specialists, PC, 8503 Arlington Blvd., Suite 400, Fairfax
West Virginia University Cancer Institute, 1 Medical Center Drive, Morgantown
Hospital Ramón y Cajal Ctra. Colmenar Viejo Km. 9,1 Planta (-)2 Dcha Oficina de Ensayos Clínicos Servicio de Oncología Médica, Madrid
Lynn Cancer Center, 701 NW 13th Street, Floor 2, Boca Raton
Cleveland Clinic, 9500 Euclid Avenue, G Building, Cleveland
Hospital Clinico Universitario Valencia Avenida Blasco Ibáñez 17 -8º, Valencia
Henry Ford Health System, 2799 W Grand Blvd., Detroit
Karmanos Cancer Institute, 4100 John R. street mail Code HW04HO, Detroit
Texas Oncology-Tyler, 910 E Houston Street, Suite 100, Tyler
University of Texas -MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston
Texas Oncology - San Antonio Medical, 5206 Research Drive, San Antonio
Texas Oncology - South Austin, 901 West 38th Street, Suite 200, Austin
Rocky Mountain Cancer Center, 1800 Williams Street, Suite 200, Denver
Huntsman Cancer Institute, 2000 Circle of Hope Drive, Salt Lake City
Innovative Clinical Research Institute, 15111 Whittier Blvd., Suite 216, Whittier
University of California San Diego, 3855 Health Sciences Drive, Mc 0987, La Jolla
University California San Francisco Thoracic Surgery and Oncology Clinic, 1600 Divisadero Street, Floor 4, San Francisco
Earle A. Chiles Research Institute Providence Cancer Center, 4805 NE Glisan Street, 2N35, Portland
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston
Valley Hospital, 223 N Van Dien Avenue, Ridgewood
The catholic University of Korea, Seoul St. Mary's hospital, 222 Banpo-daero, Seoul
Severance Hospital, Yonsei University Health System 50-1 Yonsei-ro, Seoul
Asan Medical Center Department of Oncology, 88, Olympic-ro 43-gil, Seoul
Antiga Guarderia-Servei d'Oncologia Hospital Vall d'Hebron. P.Vall Hebron 119-129, Barcelona
Lead Sponsor
Collaborators (1)
AstraZeneca
INDUSTRY
Incyte Corporation
INDUSTRY